WO2016108507A3 - Composite tablet for oral administration comprising melatonin and sertraline - Google Patents

Composite tablet for oral administration comprising melatonin and sertraline Download PDF

Info

Publication number
WO2016108507A3
WO2016108507A3 PCT/KR2015/014205 KR2015014205W WO2016108507A3 WO 2016108507 A3 WO2016108507 A3 WO 2016108507A3 KR 2015014205 W KR2015014205 W KR 2015014205W WO 2016108507 A3 WO2016108507 A3 WO 2016108507A3
Authority
WO
WIPO (PCT)
Prior art keywords
oral administration
sertraline
melatonin
composite tablet
pharmaceutically acceptable
Prior art date
Application number
PCT/KR2015/014205
Other languages
French (fr)
Korean (ko)
Other versions
WO2016108507A2 (en
Inventor
조재평
서영대
Original Assignee
건일제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 건일제약 주식회사 filed Critical 건일제약 주식회사
Publication of WO2016108507A2 publication Critical patent/WO2016108507A2/en
Publication of WO2016108507A3 publication Critical patent/WO2016108507A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a composite tablet for oral administration and a method for manufacturing the same, the composite tablet for oral administration comprising: a sustained release layer including melatonin or a pharmaceutically acceptable salt thereof, and a gel-forming polymer as a sustained release agent; and an immediate release layer including sertraline or a pharmaceutically acceptable salt thereof.
PCT/KR2015/014205 2014-12-31 2015-12-23 Composite tablet for oral administration comprising melatonin and sertraline WO2016108507A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140195829A KR20160081646A (en) 2014-12-31 2014-12-31 An oral composite tablet containing melatonin and sertraline
KR10-2014-0195829 2014-12-31

Publications (2)

Publication Number Publication Date
WO2016108507A2 WO2016108507A2 (en) 2016-07-07
WO2016108507A3 true WO2016108507A3 (en) 2016-08-25

Family

ID=56285117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/014205 WO2016108507A2 (en) 2014-12-31 2015-12-23 Composite tablet for oral administration comprising melatonin and sertraline

Country Status (3)

Country Link
KR (1) KR20160081646A (en)
TW (1) TW201626990A (en)
WO (1) WO2016108507A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514688A (en) * 2002-09-11 2006-05-11 エラン ファーマ インターナショナル，リミティド Gel-stabilized nanoparticle active substance composition
KR100680574B1 (en) * 2002-02-01 2007-02-08 데포메드 인코퍼레이티드 Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2008095142A1 (en) * 2007-01-31 2008-08-07 Methylation Sciences International Srl Extended release pharmaceutical formulations of s-adenosylmethionine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100680574B1 (en) * 2002-02-01 2007-02-08 데포메드 인코퍼레이티드 Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
JP2006514688A (en) * 2002-09-11 2006-05-11 エラン ファーマ インターナショナル，リミティド Gel-stabilized nanoparticle active substance composition
WO2008095142A1 (en) * 2007-01-31 2008-08-07 Methylation Sciences International Srl Extended release pharmaceutical formulations of s-adenosylmethionine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KASIMAY, O. ET AL.: "Exogenous Melatonin Delays Gastric Emptying Rate.", JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, vol. 56, no. 4, 2005, pages 543 - 553 *
O'REARDON, J. P . ET AL.: "A Randomized, Placebo-controlled Trial of Sertraline in the Treatment of Night Eating Syndrome", AMERICAN JOURNAL OF PSYCHIATRY, vol. 163, no. 5, 2006, pages 893 - 898 *

Also Published As

Publication number Publication date
TW201626990A (en) 2016-08-01
KR20160081646A (en) 2016-07-08
WO2016108507A2 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
EP3453707A4 (en) Benzazepine derivative, preparation method, pharmaceutical composition and use thereof
EP3452026A4 (en) The manufacturing methods, compositions, and medical applications of orally administered cannabis pharmaceuticals
EP3486242A4 (en) Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof
EP3133068A4 (en) Amide derivatives and pharmaceutically acceptable salts thereof, preparation method therefor and medicinal application thereof
JP2015147774A5 (en)
WO2015165413A8 (en) New stable antibody-drug conjugate, preparation method therefor, and use thereof
MX362838B (en) Extended release, abuse deterrent pharmaceutical compositions.
EP3582741C0 (en) Systems and methods for the fabrication of tablets, including pharmaceutical tablets
EP3663293A4 (en) Substituted penta- and hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof
PH12016501841A1 (en) Immunosuppressant formulation
MX2016014622A (en) Drug delivery systems and related methods of use.
WO2014204881A8 (en) Delayed release cysteamine bead formulation
EP3421038A4 (en) Naphthyridine compound, pharmaceutical composition and use thereof
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
EP3406602A4 (en) 1-sulfonamido-4-aryloxy compound, and preparation method and medicinal application thereof
JP2017197541A5 (en)
EP3313374A4 (en) Amphiphilic polymers encapsulating therapeutically active agents, process of preparing same and use thereof
EP3670511A4 (en) Tetrahydroprotoberberine compound, preparation method therefor and uses thereof, and pharmaceutical composition
EP3450450A4 (en) Vancomycin derivative, preparation method, pharmaceutical composition and use thereof
EP3694522A4 (en) Bi-layer pharmaceutical tablet formulation
EP3539978A4 (en) Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
EP3530654A4 (en) Quinolinyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition thereof, and use thereof
EP3453390A4 (en) Polymerized drug-containing pharmaceutical composition
EP3401685A4 (en) Diagnostic agent and medicine comprising adamts13 as main ingredient

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15875601

Country of ref document: EP

Kind code of ref document: A2